Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
NPJ Genomic Medicine|May 22, 2021
Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicityErika N Scott, Galen E B Wright, Britt I Drögemöller, et al.
The Lancet. Child & Adolescent Health|February 14, 2021
Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort studyDiana J Moke, Chunqiao Luo, Joshua Millstein, et al.
Therapeutic Drug Monitoring|July 12, 2011
CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot studySondra VanderVaart, Howard Berger, Johanna Sistonen, et al.
British Journal of Clinical Pharmacology|May 20, 2016
Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicityFolefac Aminkeng, Colin J D Ross, Shahrad R Rassekh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer PatientsBritt I Drögemöller, Beth Brooks, Carol Critchley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2023
Intravenous N-Acetylcysteine to Prevent Cisplatin-Induced Hearing Loss in Children: A Nonrandomized Controlled Phase I TrialEtan Orgel, Kristin R Knight, Yueh-Yun Chi, et al.
Archives of Women'S Mental Health|July 7, 2021
A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancyCatriona Hippman, Caitlin Slomp, Emily Morris, et al.
Nature Genetics|November 10, 2009
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapyColin J D Ross, Hagit Katzov-Eckert, Marie-Pierre Dubé, et al.
Pageof 10